Exercising the nuclear option to treat cholestasis: CAR and PXR ligands

Hepatology

Volumn 42, Issue 2, 2005, Pages 266-269

  Karpen, Saul J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONSTITUTIVE ANDROSTANE RECEPTOR; PREGNANE X RECEPTOR; XENOBIOTIC AGENT;

BILE ACID METABOLISM; CHOLESTASIS; DETOXIFICATION; EDITORIAL; GENE ACTIVATION; HUMAN; LIVER FUNCTION; LIVER METABOLISM; PRIORITY JOURNAL;

ANIMALS; CHOLESTASIS; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; TRANSCRIPTION FACTORS;

EID: 23044445820     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20833     Document Type: Editorial

References (23)

1. Goodwin B, Kliewer SA. Nuclear Receptors: I. Nuclear receptors and bile acid homeostasis. Am J Physiol Gastrointest Liver Physiol 2002;282: G926-G931.
2. Kuipers F, Claudel T, Sturm E, Staels B. The Farnesoid X Receptor (FXR) as Modulator of Bile Acid Metabolism. Rev Endocr Metab Dis 2004;5:319.
3. Karpen SJ. Nuclear receptor regulation of hepatic function. J Hepatol 2002;36:832-850.
4. Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 2003;112:1678-1687.
5. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003;125:825-838.
6. Jansen PL, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJ, et al. Hepatocanalicular Bile Salt Export Pump Deficiency in Patients With Progressive Familial Intrahepatic Cholestasis. Gastroenterology 1999;117:1370-1379.
7. Wagner M, Halilbasic E, Marschall H-U, Zollner G, Fickert P, Langner C, et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. HEPATOLOGY 2005;42: 420-430.
8. Gronemeyer H, Gustafsson J-A, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;3:950-964.
9. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003;83:633-671.
10. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005;94:1169-1186.
11. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003;42:1331-1357.
12. Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 2003;55:649-673.
13. Zhang J, Huang W, Qatanani M, Evans RM, Moore DD. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J Biol Chem 2004;279: 49517-49522.
14. Wei P, Zhang J, Dowhan DH, Han Y, Moore DD. Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenomics J 2002;2:117-126.
15. Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 2002;43:359-364.
16. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 2001;98:3369-3374.
17. Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, et al. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). PNAS 2003;100:4156-4161.
18. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-1940.
19. Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch Dis Child 1993; 69:141-143.
20. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. HEPATOLOGY 2003;38: 1008-1017.
21. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-1115.
22. Thompson RP, Williams R. Treatment of chronic intrahepatic cholestasis with phenobarbitone. Lancet 1967;2:646-648.
23. Popper H. Cholestasis: the future of a past and present riddle. HEPATOLOGY 1981;1:187-191.